Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer
Figure 2
Mean plasma concentration-versus-time profiles of motesanib following once- or twice-daily oral administration in combination with panitumumab and gemcitabine/cisplatin chemotherapy. Data are mean (±SD). Different due to missing or excluded values. BID: twice daily; QD: once daily.